Cyclocommunol
Cyclocommunol is a GST inhibitor with an IC50 of 3.0 μM. Cyclocommunol downregulates the expression of the anti-apoptotic (apoptosis) protein Mcl-1, reduces the levels of phosphorylated Akt and mTOR, and induces caspase-dependent apoptosis, reactive oxygen species (ROS) production and autophagy. Cyclocommunol can be used in research related to oral squamous cell carcinoma, breast cancer, lung cancer, norovirus-induced gastroenteritis and bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 145643-96-5
- Formula: C20H16O6
- Molecular Weight:352.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Mcl-1 |
Akt |
mTOR |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Ca9-22 | IC50 |
5.6 μM
|
Suppression of cell viability against human oral squamous cell carcinoma Ca922 cells incubated for 24 hrs by MTT assay.
Suppression of cell viability against human oral squamous cell carcinoma Ca922 cells incubated for 24 hrs by MTT assay.
|
29433680 |
| Ca9-22 | IC50 |
5.0 μM
|
Suppression of cell viability against human oral squamous cell carcinoma Ca922 cells incubated for 48 hrs by MTT assay.
Suppression of cell viability against human oral squamous cell carcinoma Ca922 cells incubated for 48 hrs by MTT assay.
|
29433680 |
| MCF7 | IC50 |
> 100 μM
|
Cytotoxicity against human MCF-7 breast cancer cells, with no detectable cytotoxicity observed.
Cytotoxicity against human MCF-7 breast cancer cells, with no detectable cytotoxicity observed.
|
40017003 |
| NCI-H460 | IC50 |
> 100 μM
|
Cytotoxicity against human NCI-H460 lung cancer cells, with no detectable cytotoxicity observed.
Cytotoxicity against human NCI-H460 lung cancer cells, with no detectable cytotoxicity observed.
|
40017003 |
Cyclocommunol (CYC) (1-5 μM; 24-48 h) potently inhibits the viability of human oral squamous cell carcinoma cell lines SCC2095 and Ca922, with IC50 values of 4.2 μM and 5.0 μM respectively after 48 h of incubation[1].
Cyclocommunol (compound 1) at concentrations greater than 100 μM shows no detectable cytotoxicity against MCF-7 human breast cancer cells or NCI-H460 human lung cancer cells[5].
Cyclocommunol (1-5 μM; 48 h) induces concentration-dependent apoptosis in human oral squamous cell carcinoma cell line SCC2095[1].
Cyclocommunol (1-5 μM; 48 h) activates caspase-dependent apoptosis, induces DNA damage, downregulates the Akt/mTOR pathway in human oral squamous cell carcinoma cell lines SCC2095 and Ca922 after 48 h of incubation, and regulates the expression of pro-apoptotic and anti-apoptotic proteins in SCC2095 cells[1].
Cyclocommunol (3 μM; 12-48 h) exhibits pro-apoptotic activity that is partially dependent on Mcl-1[1].
Cyclocommunol (3 μM; 3 h) induces reactive oxygen species production in the human oral squamous cell carcinoma cell line SCC2095[1].
Cyclocommunol (2-5 μM; 48 h) induces autophagy in the human oral squamous cell carcinoma cell line SCC2095[1].
Cyclocommunol (compound 5) at 100 μM weakly inhibits 15-LOX activity[2].
Cyclocommunol (compound 8) potently inhibits GST activity in cell-free biochemical assays, with an IC50 value of 3.0 μM[3].
Cyclocommunol exhibits weak antibacterial activity against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Salmonella enterica in agar diffusion assays[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SCC2095 and Ca922 human oral squamous cell carcinoma cells
-
Concentration:1, 2, 3, 5 μM
-
Incubation Time:24, 48 h
-
Result:Suppressed cell viability in both cell lines in a concentration- and time-dependent manner.
-
Cell Line:SCC2095 human oral squamous cell carcinoma cells
-
Concentration:1, 2, 3, 5 μM
-
Incubation Time:48 h
-
Result:Increased the percentage of apoptotic cells in a concentration-dependent manner.
-
Cell Line:SCC2095 and Ca922 human oral squamous cell carcinoma cells
-
Concentration:1, 2, 3, 5 μM
-
Incubation Time:48 h
-
Result:Caused concentration-dependent PARP cleavage, caspase-9 activation, caspase-3 activation, increased phosphorylation of p53 and H2AX, downregulated phosphorylation of Akt (Ser473) and mTOR (Ser2448), decreased expression of anti-apoptotic proteins Mcl-1 and survivin, and increased expression of pro-apoptotic protein Bax in SCC2095 cells.
Downregulated phosphorylation of Akt and mTOR in a concentration-dependent manner in Ca922 cells.
-
Cell Line:SCC2095 human oral squamous cell carcinoma cells
-
Concentration:2, 3, 5 μM
-
Incubation Time:48 h
-
Result:Induced formation of GFP-LC3 puncta (autophagosomes) at 5 μM.
Caused concentration-dependent upregulation of LC3B-II, p62, and Atg5 protein expression.
Increased the percentage of cells with acidic vesicular organelles to 24.1% at 2 μM and 30.6% at 3 μM.
-
Cell Line:SCC2095 human oral squamous cell carcinoma cells
-
Concentration:3 μM
-
Incubation Time:12, 48 h
-
Result:Partially reversed cyclocommunol-mediated PARP cleavage and caspase-3 activation via Mcl-1 overexpression.
Partially rescued cell viability from cyclocommunol-induced cytotoxicity via Mcl-1 overexpression.
Decreased Mcl-1 expression in a time-dependent manner at 3 μM over 48 h.
Chemical Information
-
CAS No. 145643-96-5
-
Molecular Weight 352.34
-
Formula C20H16O6
-
SMILES
C/C(C)=C\C1C2=C(OC3=C(C(O)=CC(O)=C3)C2=O)C4=CC=C(O)C=C4O1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cyclocommunol Related Classifications
HY-N3665 Related Classifications
Powered by Bioz